Developing a new treatment for lupus using engineered nanoparticles and cyclosporine A.
Engineering the next generation nanoparticle-cyclosporine A therapy in lupus
This study is looking at a new way to help people with lupus by using tiny particles to deliver a medication more effectively, which could make the treatment safer and work better for managing the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama in Tuscaloosa NIH-funded |
| Lab location | 1 site (Tuscaloosa, United States) |
| Project ID | NIH-10685437 on NIH RePORTER |
What this research studies
This research focuses on improving treatment options for systemic lupus erythematosus (SLE), an autoimmune disease that can severely impact various organs. The approach involves using engineered nanoparticles to enhance the delivery of cyclosporine A, a drug that suppresses the immune system but has had limited effectiveness due to poor targeting and side effects. By specifically targeting lymphoid tissues, particularly in the gut, the study aims to increase the drug's bioavailability and reduce toxicity. Patients may benefit from a more effective and safer treatment option for lupus if this innovative method proves successful.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with systemic lupus erythematosus who are seeking better treatment options.
Not a fit: Patients with lupus who are not responsive to immunosuppressive therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and safer treatment for lupus patients.
How similar studies have performed: While the use of nanoparticles in drug delivery is a growing field, this specific approach targeting lupus with cyclosporine A is novel and has not been extensively tested.
Where this research is happening
Tuscaloosa, United States
- University of Alabama in Tuscaloosa — Tuscaloosa, United States (Active)
Researchers
- Principal investigator: Majeti, Ravikumar N — University of Alabama in Tuscaloosa
- Study coordinator: Majeti, Ravikumar N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.